Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cole Wayant

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Current Treatment Options in Oncology|June 27, 2025
Interrupted Systemic Therapy (Drug Holiday) for Metastatic Sarcoma: Is It Safe?Alessandra Maleddu, Cole Wayant
BMJ Evidence-Based Medicine|October 27, 2019
TIDieR checklist evaluation of clinical trial intervention reporting for recent FDA-approved anticancer medicationsCole Wayant, Richard Bindernagel, Matt Vassar
JAMA|November 7, 2018
Evaluation of Lowering the P Value Threshold for Statistical Significance From .05 to .005 in Previously Published Randomized Clinical Trials in Major Medical JournalsCole Wayant, Jared Scott, Matt Vassar
BMJ Evidence-Based Medicine|October 5, 2018
Use of a meta-research team to facilitate evidence-based medicine to the next generationMichael Bibens, Matt Vassar, Cole Wayant
BMJ Evidence-Based Medicine|July 26, 2018
Transparency of industry payments needed in clinical practice guidelinesMatt Vassar, Michael Bibens, Cole Wayant
BMJ Evidence-Based Medicine|November 17, 2019
On reporting and interpreting statistical significance and p values in medical researchHerman Aguinis, Matt Vassar, Cole Wayant
Critical Reviews in Oncology/Hematology|March 16, 2020
Methodological quality of oncology noninferiority clinical trialsCole Wayant, Andrew Ross, Matt Vassar
JAMA|April 17, 2019
Lowering the P Value Threshold-ReplyCole Wayant, Jared Scott, Matt Vassar
European Journal of Cancer (Oxford, England : 1990)|April 22, 2022
Early discontinuation and failure to publish clinical trials of haematologic cancer interventions: A retrospective observational studyCole Wayant, Kaylea Feldman, Morgan Garrett
Journal of Cancer Policy|May 13, 2022
The accelerated approval pathway in oncology: Balancing the benefits and potential harmsCole Wayant, Ghulam Rehman Mohyuddin, Vinay Prasad
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Current Treatment Options in Oncology|June 27, 2025
Interrupted Systemic Therapy (Drug Holiday) for Metastatic Sarcoma: Is It Safe?Alessandra Maleddu, Cole Wayant
BMJ Evidence-Based Medicine|October 27, 2019
TIDieR checklist evaluation of clinical trial intervention reporting for recent FDA-approved anticancer medicationsCole Wayant, Richard Bindernagel, Matt Vassar
JAMA|November 7, 2018
Evaluation of Lowering the P Value Threshold for Statistical Significance From .05 to .005 in Previously Published Randomized Clinical Trials in Major Medical JournalsCole Wayant, Jared Scott, Matt Vassar
BMJ Evidence-Based Medicine|October 5, 2018
Use of a meta-research team to facilitate evidence-based medicine to the next generationMichael Bibens, Matt Vassar, Cole Wayant
BMJ Evidence-Based Medicine|July 26, 2018
Transparency of industry payments needed in clinical practice guidelinesMatt Vassar, Michael Bibens, Cole Wayant
BMJ Evidence-Based Medicine|November 17, 2019
On reporting and interpreting statistical significance and p values in medical researchHerman Aguinis, Matt Vassar, Cole Wayant
Critical Reviews in Oncology/Hematology|March 16, 2020
Methodological quality of oncology noninferiority clinical trialsCole Wayant, Andrew Ross, Matt Vassar
JAMA|April 17, 2019
Lowering the P Value Threshold-ReplyCole Wayant, Jared Scott, Matt Vassar
European Journal of Cancer (Oxford, England : 1990)|April 22, 2022
Early discontinuation and failure to publish clinical trials of haematologic cancer interventions: A retrospective observational studyCole Wayant, Kaylea Feldman, Morgan Garrett
Journal of Cancer Policy|May 13, 2022
The accelerated approval pathway in oncology: Balancing the benefits and potential harmsCole Wayant, Ghulam Rehman Mohyuddin, Vinay Prasad
Pageof 7